Literature DB >> 18778556

Rash from EGFR inhibitors: opportunities and challenges for palliation.

Benjamin M Solomon1, Aminah Jatoi.   

Abstract

The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18778556     DOI： 10.1007/s11912-008-0048-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  22 in total

1.  Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.

Authors: 
Journal:  Cancer Biol Ther       Date:  2006-04       Impact factor: 4.742

2.  The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.

Authors:  Mario E Lacouture; Surendra Basti; Jyoti Patel; Al Benson
Journal:  J Support Oncol       Date:  2006-05

3.  Inhibition of PTEN and activation of Akt by menadione.

Authors:  Kyoko Yoshikawa; Kiyomi Nigorikawa; Mariko Tsukamoto; Namiko Tamura; Kaoru Hazeki; Osamu Hazeki
Journal:  Biochim Biophys Acta       Date:  2006-12-24

Review 4.  Mechanisms of cutaneous toxicities to EGFR inhibitors.

Authors:  Mario E Lacouture
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Authors:  John R Johnson; Martin Cohen; Rajeshwari Sridhara; Yeh-Fong Chen; Gene M Williams; John Duan; Jogarao Gobburu; Brian Booth; Kimberly Benson; John Leighton; Li Shan Hsieh; Nallalerumal Chidambaram; Paul Zimmerman; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

6.  Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.

Authors:  K J Busam; P Capodieci; R Motzer; T Kiehn; D Phelan; A C Halpern
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

7.  Erlotinib-induced florid acneiform rash complicated by extensive impetiginization.

Authors:  S H Kardaun; K F van Duinen
Journal:  Clin Exp Dermatol       Date:  2007-11-03       Impact factor: 3.470

8.  2-Methyl-1,4-naphthoquinone, vitamin K(3), decreases gap-junctional intercellular communication via activation of the epidermal growth factor receptor/extracellular signal-regulated kinase cascade.

Authors:  Lars-Oliver Klotz; Pauline Patak; Niloofar Ale-Agha; Darius P Buchczyk; Kotb Abdelmohsen; P Arne Gerber; Claudia von Montfort; Helmut Sies
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

9.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

10.  FDA drug approval summary: panitumumab (Vectibix).

Authors:  Ruthann M Giusti; Kaushikkumar A Shastri; Martin H Cohen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2007-05
View more
  14 in total

1.  E-mail and photographs: a case report of a patient-initiated diagnostic tool in the era of electronic communication.

Authors:  Mindy Hartgers; Aminah Jatoi
Journal:  J Palliat Med       Date:  2010-03       Impact factor: 2.947

Review 2.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Authors:  Rodrigo Dienstmann; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Oncologist       Date:  2011-12-01

3.  A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors.

Authors:  Shawnta Coleman; Irina Kovtun; Phuong L Nguyen; Mark Pittelkow; Aminah Jatoi
Journal:  Psychooncology       Date:  2010-09-23       Impact factor: 3.894

4.  Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.

Authors:  Benjamin M Solomon; Aminah Jatoi
Journal:  J Palliat Med       Date:  2011-01-12       Impact factor: 2.947

5.  Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report.

Authors:  Kenkichiro Taira; Kazunori Fujiwara; Takahiro Fukuhara; Tsuyoshi Morisaki; Satoshi Koyama; Ryohei Donishi; Hiromi Takeuchi
Journal:  Yonago Acta Med       Date:  2020-11-24       Impact factor: 1.641

6.  Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.

Authors:  Thomas P J Garrett; Antony W Burgess; Hui K Gan; Rod B Luwor; Glenn Cartwright; Francesca Walker; Suzanne G Orchard; Andrew H A Clayton; Edouard C Nice; Julie Rothacker; Bruno Catimel; Webster K Cavenee; Lloyd J Old; Elisabeth Stockert; Gerd Ritter; Timothy E Adams; Peter A Hoyne; Dane Wittrup; Ginger Chao; Jennifer R Cochran; Cindy Luo; Mezhen Lou; Trevor Huyton; Yibin Xu; W Douglas Fairlie; Shenggen Yao; Andrew M Scott; Terrance G Johns
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

7.  Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.

Authors:  Aminah Jatoi; Erin M Green; Kendrith M Rowland; Daniel J Sargent; Steven R Alberts
Journal:  Oncology       Date:  2009-07-22       Impact factor: 2.935

Review 8.  Skin toxicities associated with epidermal growth factor receptor inhibitors.

Authors:  Tianhong Li; Roman Perez-Soler
Journal:  Target Oncol       Date:  2009-05-19       Impact factor: 4.493

9.  A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

Authors:  Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O'Neil; Ruey-Min Lee; Mark Zalupski; Janet Dancey; Helen Chen; Michael Grever; Charis Eng; Miguel Villalona-Calero
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

10.  Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.

Authors:  Loretta A Williams; Emre Yucel; Jorge E Cortes; Charles S Cleeland
Journal:  Clin Investig (Lond)       Date:  2013-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.